TW202123976A - 穩定濃縮之放射性醫藥組合物 - Google Patents

穩定濃縮之放射性醫藥組合物 Download PDF

Info

Publication number
TW202123976A
TW202123976A TW109131644A TW109131644A TW202123976A TW 202123976 A TW202123976 A TW 202123976A TW 109131644 A TW109131644 A TW 109131644A TW 109131644 A TW109131644 A TW 109131644A TW 202123976 A TW202123976 A TW 202123976A
Authority
TW
Taiwan
Prior art keywords
pharmaceutical composition
salt
acid
ascorbic acid
concentration
Prior art date
Application number
TW109131644A
Other languages
English (en)
Chinese (zh)
Inventor
馬里西歐 Ｆ 馬里亞尼
凡雀絲卡 歐蘭笛
羅倫薩 弗卡薩
羅倫左 紗雀堤
馬狄雅 塔帝斯科
多納托 巴巴托
Original Assignee
義大利商先進艾斯雷特應用（義大利）公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 義大利商先進艾斯雷特應用（義大利）公司 filed Critical 義大利商先進艾斯雷特應用（義大利）公司
Publication of TW202123976A publication Critical patent/TW202123976A/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/088—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins conjugates with carriers being peptides, polyamino acids or proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/12—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes, characterized by a special physical form, e.g. emulsions, dispersions, microcapsules
    • A61K51/121—Solutions, i.e. homogeneous liquid formulation

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Optics & Photonics (AREA)
  • Physics & Mathematics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dispersion Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
TW109131644A 2019-09-16 2020-09-15 穩定濃縮之放射性醫藥組合物 TW202123976A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP19197607 2019-09-16
EP19197607.5 2019-09-16

Publications (1)

Publication Number Publication Date
TW202123976A true TW202123976A (zh) 2021-07-01

Family

ID=67981980

Family Applications (1)

Application Number Title Priority Date Filing Date
TW109131644A TW202123976A (zh) 2019-09-16 2020-09-15 穩定濃縮之放射性醫藥組合物

Country Status (11)

Country Link
US (2) US20220401593A1 (https=)
EP (1) EP4031193A1 (https=)
JP (2) JP7762648B2 (https=)
KR (1) KR20220063218A (https=)
CN (1) CN114728088A (https=)
AR (1) AR119974A1 (https=)
AU (1) AU2020349002B2 (https=)
CA (1) CA3154302A1 (https=)
IL (1) IL291315A (https=)
TW (1) TW202123976A (https=)
WO (1) WO2021052960A1 (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4442285A1 (en) * 2021-11-30 2024-10-09 Nihon Medi-Physics Co., Ltd. Stabilized radiopharmaceutical composition
CN114404618A (zh) * 2022-03-28 2022-04-29 北京先通国际医药科技股份有限公司 放射性药物水溶液及其用途
CN114404619A (zh) * 2022-03-28 2022-04-29 北京先通国际医药科技股份有限公司 放射性药物水溶液及其制备方法和用途
CN116920129A (zh) * 2022-04-02 2023-10-24 北京先通国际医药科技股份有限公司 放射性药物水溶液及其制备方法和用途
JP2026505341A (ja) 2023-02-08 2026-02-13 ノバルティス アーゲー 神経膠芽腫を治療するための方法
IL322257A (en) 2023-02-23 2025-09-01 Novartis Ag Methods of treating breast cancer
CN121793988A (zh) 2023-09-13 2026-04-03 东丽株式会社 癌的治疗、预防和/或诊断用药物组合物
TW202527951A (zh) 2023-12-15 2025-07-16 瑞士商諾華公司 用於治療乳腺癌的方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5139678B2 (ja) * 2003-07-24 2013-02-06 ブラッコ・イメージング・ソシエタ・ペル・アチオニ 安定な放射性医薬品組成物およびその製法
WO2008009444A1 (en) 2006-07-19 2008-01-24 Van Dulmen, Adrianus, A. Use of ethanol for stabilizing a single-vial liquid formulation of a radiolabeled peptide
ES2745635T3 (es) 2012-09-25 2020-03-03 Advanced Accelerator Applications Usa Inc Antagonistas de GRPR para la detección, diagnóstico y tratamiento del cáncer positivo para GRPR

Also Published As

Publication number Publication date
AR119974A1 (es) 2022-01-26
EP4031193A1 (en) 2022-07-27
WO2021052960A1 (en) 2021-03-25
US20220401593A1 (en) 2022-12-22
JP2022548875A (ja) 2022-11-22
IL291315A (en) 2022-05-01
CN114728088A (zh) 2022-07-08
KR20220063218A (ko) 2022-05-17
US20250332301A1 (en) 2025-10-30
JP2026031934A (ja) 2026-02-25
AU2020349002A1 (en) 2022-04-28
JP7762648B2 (ja) 2025-10-30
AU2020349002B2 (en) 2024-05-02
CA3154302A1 (en) 2021-03-25

Similar Documents

Publication Publication Date Title
TW202123976A (zh) 穩定濃縮之放射性醫藥組合物
TWI878344B (zh) 放射性標記grpr拮抗劑之方法及其套組
JP2021506784A (ja) 鉛またはトリウム放射性核種に連結されたｐｓｍａ標的化化合物を含む錯体
CN110678227A (zh) 使用与放射性同位素螯合的奥曲肽衍生物治疗过表达生长抑素受体的癌细胞
CN118647415A (zh) 包含225锕标记的络合物和铋多价螯合剂的药物组合物
KR102840765B1 (ko) 방사성제약 용도를 위한 소마토스타틴 유사체를 함유하는 조성물
TW202120129A (zh) 用作為診療劑之放射標記grpr拮抗劑
RU2839656C1 (ru) Стабильная концентрированная радиофармацевтическая композиция
CN113195005B (zh) 包含放射性标记的grpr拮抗剂和表面活性剂的药物组合物
RU2855011C1 (ru) Способы мечения радиоактивными изотопами антагонистов grpr и наборы на для их осуществления
WO2024249352A1 (en) Methods for treating sstr positive cancer